Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- Merck & Co. (MRK) has delivered stronger year-to-date performance compared to Novartis AG (NVS), with notable outperformance over broader market benchmarks in recent market activity.
- Both companies operate in the pharmaceutical sector, with MRK benefiting from robust demand for its oncology portfolio and NVS maintaining a diversified pipeline across multiple therapeutic areas.
- Analyst sentiment toward MRK has shown upward revisions in price targets amid positive earnings momentum, while NVS exhibits more moderate growth trajectories in recent comparisons.
- Relative momentum favors MRK in the near term, driven by product-specific catalysts, whereas NVS offers stability through its established global presence and dividend profile.
- Sector exposure remains similar, though risk factors differ with MRK facing patent considerations on key assets and NVS navigating broader competitive dynamics in generics and innovation.
- Market positioning highlights trade-offs between MRK’s growth-oriented profile and NVS’s balanced approach to revenue streams and operational efficiency.
Introduction
This comparison examines Merck & Co. (MRK) and Novartis AG (NVS), two leading pharmaceutical companies whose stocks often attract attention from institutional investors, portfolio managers, and traders seeking exposure to the healthcare sector. The analysis focuses on observable factors such as recent price behavior, business fundamentals, and relative positioning to help market participants evaluate potential opportunities in a dynamic environment. Investors interested in sector rotation, relative strength analysis, or diversified healthcare allocations may find this stock comparison particularly relevant for assessing performance differentials and market sentiment shifts.
MRK Overview and Recent Performance
Merck & Co. (MRK) is a global pharmaceutical company with a primary focus on innovative medicines in oncology, vaccines, and animal health. Its flagship product, Keytruda, continues to drive significant revenue contributions. In recent weeks, MRK stock has shown resilience amid broader market fluctuations, closing near $127.50 following trading sessions with modest daily movements. Year-to-date returns have reached approximately 22.9%, outpacing the S&P 500’s 8.94% gain during the same period. Recent earnings results highlighted beats on revenue and adjusted metrics, supported by strong sales in core products, which prompted analysts to raise price targets into the $138–$155 range. Sentiment has been influenced by pipeline developments and updated full-year guidance, contributing to a generally constructive tone in market activity.
NVS Overview and Recent Performance
Novartis AG (NVS) is a multinational pharmaceutical firm with a broad portfolio spanning oncology, cardiovascular, neuroscience, and ophthalmology, complemented by a generics division. The company maintains a global footprint and emphasizes both innovative therapies and operational efficiencies. In recent market activity, NVS has recorded more moderate gains relative to peers, with one-year performance trailing some sector leaders. Stock behavior has reflected steady but less aggressive momentum compared to certain competitors, aligning with a diversified approach to growth drivers. Broader comparisons indicate NVS delivering returns in the 15–28% range over select periods, supported by stable fundamentals and ongoing pipeline updates, though it has not matched the pace of stronger performers in the pharmaceutical space during the latest market cycles.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a platform offering hundreds of automated strategies that cover thousands of different tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this trending section, based on metrics such as historical performance ranges, win rates, and drawdown profiles that can vary widely across bots. Available strategies encompass diverse trading styles, timeframes, risk parameters, and ticker sets, allowing users to explore options tailored to equities, sectors, or broader indices. This resource provides traders with data-driven insights into automated approaches without endorsing any specific outcome. Explore the full collection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
In business model terms, Merck & Co. (MRK) emphasizes high-growth innovative therapies with heavy reliance on a few flagship assets, while Novartis AG (NVS) balances innovation with a wider array of established products and a generics segment for steadier cash flows. Growth drivers for MRK center on oncology momentum and new product launches, contrasting with NVS’s focus on pipeline diversification and cost management. Recent momentum has favored MRK, as evidenced by superior year-to-date and comparative returns, though NVS provides a more tempered risk profile through geographic breadth. Sector exposure overlaps significantly in healthcare, yet MRK carries elevated sensitivity to patent cliffs on key drugs, whereas NVS contends with generic competition and regulatory nuances across markets. Market sentiment reflects these contrasts, with MRK attracting more frequent analyst upgrades amid positive catalysts and NVS appealing to those prioritizing consistency over rapid appreciation.
Tickeron AI Verdict
Based on observable factors including stronger relative performance trends, consistent analyst target revisions, and product-driven catalysts, Tickeron’s AI would likely assign a probabilistic edge to Merck & Co. (MRK) in the current environment over Novartis AG (NVS). This assessment considers trend consistency and positioning differentials without implying certainty, as market conditions can shift and both stocks remain subject to sector-specific variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a StrongBuy and NVS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 4 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 7 bullish TA indicator(s).
- MRK’s TA Score: 5 bullish, 4 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +2.80% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
MRK is expected to report earnings on Aug 04, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | NVS | MRK / NVS | |
| Capitalization | 324B | 295B | 110% |
| EBITDA | 19.4B | 22.4B | 87% |
| Gain YTD | 26.345 | 15.830 | 166% |
| P/E Ratio | 36.92 | 23.42 | 158% |
| Revenue | 65.8B | 56.6B | 116% |
| Total Cash | N/A | 6.98B | - |
| Total Debt | 49.1B | 47B | 104% |
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 42 | 6 | |
SMR RATING 1..100 | 47 | 28 | |
PRICE GROWTH RATING 1..100 | 8 | 46 | |
P/E GROWTH RATING 1..100 | 7 | 23 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (87). This means that NVS’s stock grew significantly faster than MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (42). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
NVS's SMR Rating (28) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (46). This means that MRK’s stock grew somewhat faster than NVS’s over the last 12 months.
MRK's P/E Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as NVS (23). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 50% | N/A |
| Stochastic ODDS (%) | 3 days ago 52% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 59% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 54% | 3 days ago 40% |
| TrendWeek ODDS (%) | 3 days ago 56% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 50% |
| Advances ODDS (%) | 3 days ago 55% | 10 days ago 52% |
| Declines ODDS (%) | 7 days ago 51% | 13 days ago 46% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 65% | 3 days ago 48% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.